P. Cassier et al. ESMO 2021 Download the poster here Poster Presentation
Category: dates
Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002
Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002
Transgene Announces Upcoming Investor Meetings
Transgene Announces Upcoming Investor Meetings
Transgene Participates in New Cancer Research Consortium
Transgene Participates in New Cancer Research Consortium
3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses
Poster BT-001 Hélène Lê et al. EUROoCS 2021 Download the Poster here Poster Presentation
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
First patient enrolled in expanded Phase II clinical trial of TG4001 + avelumab vs avelumab alone in patients with HPV16-positive anogenital cancers
20210624 Transgene TG4001.12 FPI EN
Transgene announces the success of its Capital Increase via a Private Placement
20210622 – Transgene – Pricing PR – ENG – V DEF website
Transgene Launches a Capital Increase via a Private Placement
Transgene – Launch CP – ENG – website
Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)
20210608 – IP Invir.IO ICI – EN